Healthcare regulation agency Frier Levitt has analyzed FDA enforcement actions against “analysis only” peptide vendors. Their summary: the FDA considers an item’s classification based upon its supposed use, not its disclaimers. When Sites contain dosage guides, reconstitution instructions, or websit